Accordingly, the current study seeks to test the involvement of HCNP reduction in cholinergic dysfunction in HCNP-pp cKO mice and to verify its potential as a therapeutic candidate for diseases with cholinergic impairment, including Alzheimer’s disease (AD) and Lewy body dementia. Here, PEBP1 is linked to Alzheimer disease.